RxDoctor Payments Data

Easwar Sundaram, MD

Neurology · Sherman, TXNPI 1679571004

Payments from drug & device makers

$5,356in general payments, 2019–2025

Across 260 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$823
  • AbbVie$507
  • Livanova USA, Inc.$493
  • Pfizer$217
  • Novartis$214
  • SK Life Science, Inc.$198
  • plus $3K from 42 others

What the payments were for

  • Travel & lodging$2575%
  • Food & beverage$5,08295%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,356 in reported general payments places this provider in the 55th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$681,862
Medicare patients
862
Services billed
42,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 46168$1,087,242
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5067$446,666
GammakedImmune Globul G/Gly/Iga Avg 4617$110,944
MayzentSiponimod11$98,308
OxycontinOxycodone Hcl75$83,489
CopaxoneGlatiramer Acetate12$79,811
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5012$74,879
QuliptaAtogepant50$59,268
Nurtec OdtRimegepant Sulfate39$52,665
XcopriCenobamate29$47,207
LinzessLinaclotide34$30,488
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,055$29,977
BriviactBrivaracetam19$26,295
Lacosamide128$26,189
UbrelvyUbrogepant13$22,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$19$1,087,242168 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$49$446,66667 claims
AbbVieQulipta, Linzess, Ubrelvy$507$112,57097 claims
NovartisMayzent$214$98,30811 claims
Teva Pharmaceuticals USA, Inc.Copaxone$88$79,81112 claims
PfizerNurtec Odt, Eliquis$217$73,78371 claims
SK Life Science, Inc.Xcopri$198$47,20729 claims
UCB, Inc.Briviact, Vimpat$823$46,13832 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$76$6,40134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,246 neurology providers in Texas.

Other neurology in Sherman

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →